In the era of COVID-19, where the world is looking for point of care treatment, in order to avoid maintain physical distance. Post the onset of COVID-19 pandemic, there has been a decline in number of patients visiting laboratories for sample collection and testing. To avoid risk of infections, patients have postponed their routine tests and medical checkups. The aforementioned concerns have encouraged stakeholders to develop novel devices and technologies that can enable patients for at-home blood collection remotely. With the advancements in molecular detection techniques and a significant reduction in the amount of sample required for testing, these miniature devices are driving sampling platform for diagnosis and monitoring towards point of care. This technique is well known for capturing minute samples of blood. These techniques are more user friendly, as compared to traditional sampling techniques which are highly invasive and may show variation in analysis.
Players Engaged in Developing Self Blood Collection and Micro Sampling Devices
There are 39 companies that are involved in developing close to 50 at-home blood collection and micro sampling devices. As per our analysis maximum number of players are located in North-America, followed by Europe. In this domain, small size companies have shown significant amount of participation, along with the involvement of some big pharmaceuticals. Amongst the total device that are involved in the at-home blood collection and micro sampling devices domain, more than 80% of the devices are having marketing approvals. Most of the device (55%) are based on the DBS technology.
Strong Intellectual Property Portfolio
The growing popularity of this domain has encouraged several stakeholders for putting in efforts to bring advancement of at-home blood collection and micro sampling. During our research, we came across through 125 patents application / granted that were related to at-home blood collection and micro sampling. It is worth mentioning that majority of patents were filed by industrial players.
The Self Blood Collection and Micro Sampling Market is anticipated to grow at a CAGR of 11%, during 2021-2030
Driven by the increasing demand point of care testing, and cost saving potential of the devices, the at-home blood collection and micro sampling device market is projected to grow at a steady pace in the foreseen future. It is worth mentioning that North America presently has the maximum share in the growth of at-home blood collection and micro sampling devices market. To get a detailed information on the key players, regulatory landscape, mergers and acquisitions, expansions, demand, installed capacity and the likely market evolution.
For further information on this domain, check out the report –